[Clinical studies on cefminox in the field of pediatrics].
A new antibiotic of cephamycin group, cefminox (CMNX, MT-141), was evaluated clinically in the treatment of bacterial infections in children. The following results were obtained. One case of lacunar tonsillitis (due to H. influenzae) and 5 cases of urinary tract infections (due to E. coli in 2 cases, mixed infection due to E. coli and E. faecalis in 1 case, due to K. pneumoniae in 1 case and causative organism was unknown in 1 case) were treated intravenously with CMNX at daily doses ranging from 58.1 to 122.7 mg/kg in 3 divided doses. One case in which the treatment was discontinued after 1 day because of rashes was excluded from assessment of efficacy. Among the remaining 5 cases, CMNX was found ineffective for 1 case of mixed infection due to E. coli and E. faecalis. However, in all of the other 4 cases excellent results were obtained. As side effects, rashes developed in 1 case and slight elevation in GOT in 1 case out of 6 cases. Blood levels following bolus intravenous injection of 20 mg/kg of CMNX were 68, 45, 27, 10.2 and 3.1 micrograms/ml at 1/2, 1, 2, 4 and 6 hours, respectively, with T 1/2 of 1.27 hours. The urinary recovery rate within the first 6 hours was 78.6%.
D000900:Anti-Bacterial Agents / Q000378:metabolism / Q000627:therapeutic use*; D002513:Cephamycins / Q000378:metabolism / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D004926:Escherichia coli / Q000187:drug effects; D005260:Female; D006193:Haemophilus influenzae / Q000187:drug effects; D006801:Humans; D007223:Infant; D007263:Infusions, Parenteral; D008297:Male; D014069:Tonsillitis / Q000188:drug therapy* / Q000378:metabolism; D014552:Urinary Tract Infections / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D002513:Cephamycins; C046079:cefminox